233 results on '"Chekerov R"'
Search Results
52. Patientinnen mit gynäkologischem Sarkom: Charakteristika aus der Online-Tumorkonferenz für seltene Tumoren
53. MONITOR VII – Behandlungsstrategie beim Low-grade Ovarialkarzinom. Eine deutschlandweite Umfrage der Charité – Berlin und Kliniken Essen Mitte mit Unterstützung der NOGGO und AGO
54. Management von Patientinnen mit gynäkologischem Sarkom – Eine Umfrage zur Behandlungspraxis der betreuenden GynäkologInnen im Rahmen der REGSA-Studie (Deutsches gynäkoonkologisches Sarkomregister) – MONITOR IX
55. Fallbericht eines dedifferenzierten Liposarkoms mit den klinischen Zeichen eines Ovarialkarzinoms sowie eine Zusammenfassung der Literatur
56. Angiosarkom des weiblichen Genitaltraktes – Fallserie eines äußerst seltenen, aggressiven und vielgesichtigen Tumors mit systematischem Review
57. Peritoneal metastasiertes High-grade-Stromasarkom – Eine Kasuistik
58. Patientinnen mit Keimstrang-Stroma-Tumor: Charakteristika aus der Online-Tumorkonferenz für seltene Tumoren
59. HE4 is the marker of choice in discriminating endometriosis from ovarian cancer in pelvic mass patients: Sub-analysis of a prospective multicentric study
60. Topotecan (T) +/- Sorafenib (S) for platinum-resistant ovarian cancer (PROC): results of doubleblind placebo-controlled randomized NOGGO - AGO intergroup trial
61. Y-box protein-1/p18 as novel serum marker for ovarian cancer diagnosis: A study by the Tumor Bank Ovarian Cancer (TOC)
62. Expression III: Erwartungen und Präferenzen von Patientinnen mit Ovarialkarzinom. Eine Umfrage an 585 Patientinnen (NOGGO/Subanalyse der ENGOT ov4-Studie)
63. Erste Ergebnisse der Expression V Studie – Berliner Umfrage zu Erwartungen und Wünsche von Patientinnen mit und ohne Migrationshintergrund und gynäkologische Malignome
64. Interimsanalyse der multizentrischen NOGGO Studie – Expression V – Umfrage zu den Erwartungen und Wünschen von Patientinnen mit gynäkologischen Malignomen und mit und ohne Migrationshintergrund
65. PARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future Perspectives
66. The european network for gynaecological oncological trial groups charta for privileged partnership
67. 995P - MONITOR VII: Treatment strategies of low grade ovarian carcinomas – A German survey of the Charité – Berlin and Kliniken Essen Mitte with support of the study groups NOGGO and AGO
68. Aktuelle Entwicklungen in der Prävention und Therapie des Hand- und Fußsyndroms
69. Implementation of an interdisciplinary Online Tumor Conference as a new tool in the management of gynaecological cancers
70. Intra- and postoperative catumaxomab in patients with epithelial ovarian cancer: safety and two-year efficacy results from a multicentre, single-arm, phase II study
71. Role of IGF1 in primary ovarian cancer – a study of the OVCAD European Consortium
72. Schwere Hypertonie und Proteinurie in 19+2 SSW bei Triploidie mit Plazentahypertrophie sowie alobärer Holoprosenzephalie
73. Prognostische Bedeutung des postoperativen Tumorrests bei Patientinnen mit epithelialem Ovarialkarzinom FIGO IIA-IV: Analyse der OVCAD Daten
74. 8007 ORAL Catumaxomab Induces Efficient Anti-tumour Activity in Vitro With Immune Cells From Ovarian Cancer Patients After Chemotherapy Treatment
75. Intra- and post-operative catumaxomab in patients with epithelial ovarian cancer: Two-year efficacy results from a multicenter, single-arm, phase II study.
76. A randomized, double-blind, placebo-controlled, multicenter phase II study to compare the efficacy and safety of sorafenib added to standard treatment with topotecan to standard treatment alone in patients with platinum-resistant recurrent ovarian cancer (TRIAS): Results of a NOGGO-AGO intergroup pilot-study.
77. First quality-of-life data of a sequential dose-dense regimen in advanced ovarian cancer: A multicenter phase II study of the Northeastern German Society of Gynecological Oncology.
78. Effect of catumaxomab on EpCAM+ tumor cells in vitro in the presence of immune effector cells from ovarian cancer patients treated with chemotherapy.
79. Are there any molecular biologic factors which explain the poorer prognosis of elderly patients with advanced ovarian cancer?
80. Use of HE4 expression in plasma to predict operative outcome in patients with ovarian cancer (OC).
81. Intraoperative immunotherapy with the trifunctional antibody catumaxomab in patients with ovarian cancer: Results from a phase II study.
82. 8029 The expression of CASA in ascites correlates with the overall survival and clinical outcome in patients with ovarian cancer
83. 8059 Multicenter survey of 323 gynaecological departments in Germany: current standards in the clinical management of borderline tumours of the ovary
84. Current management of borderline ovarian tumors: A multicenter survey of 323 clinics in Germany, on behalf of the North-Eastern German Society of Gynecological Oncology (NOGGO)
85. How is the clinical practice? Pegylated liposomal doxorubicin in the therapy of patients with recurrent ovarian cancer: Results of a German observational study
86. Online tumor conference in the clinical management of gynecological cancer: experience from a pilot study in Germany
87. Interdisciplinary Online Tumorconference: Implementation of a new tool in the management of gynaecological cancers in Germany
88. Effects of polymorphism (plm) in interleukin (IL) 1 and IL10 genes on surgery outcome in ovarian cancer (OC)
89. Zytostatikaextravasate
90. Clinical management of borderline tumours of the ovary: results of a multicentre survey of 323 clinics in Germany.
91. Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -A study of the OVCAD consortium
92. The european network for gynaecological oncological trial groups charta for privileged partnership
93. Ovarian cancer management in an ESGO ovarian cancer center of excellence: a systematic case study of the interprofessional and interdisciplinary interaction.
94. Pre-Operative Malnutrition in Patients with Ovarian Cancer: What Are the Clinical Implications? Results of a Prospective Study.
95. The KORE-INNOVATION trial, a prospective controlled multi-site clinical study to implement and assess the effects of an innovative peri-operative care pathway for patients with ovarian cancer: rationale, methods and trial design.
96. Pazopanib with Topotecan weekly for patients with platinum-resistant or intermediate-sensitive recurrent ovarian cancer: results of a multicentre, open label phase I/II study (TOPAZ).
97. Treatment strategies in patients with gynecological sarcoma: Results of the prospective intergroup real-world registry for gynecological sarcoma in Germany (REGSA-NOGGO RU1).
98. Can a morphological description of the peritoneal carcinomatosis in advanced ovarian cancer add prognostic information? Analysis of 1686 patients of the tumor bank ovarian cancer.
99. Predictive biomarker for surgical outcome in patients with advanced primary high-grade serous ovarian cancer. Are we there yet? An analysis of the prospective biobank for ovarian cancer.
100. HE4 as a serum biomarker for the diagnosis of pelvic masses: a prospective, multicenter study in 965 patients.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.